Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Cash from Investing Activities (2016 - 2023)

Historic Cash from Investing Activities for Alaunos Therapeutics (TCRT) over the last 13 years, with Q4 2023 value amounting to $1.5 million.

  • Alaunos Therapeutics' Cash from Investing Activities rose 171612.9% to $1.5 million in Q4 2023 from the same period last year, while for Sep 2024 it was $1.5 million, marking a year-over-year increase of 70120.0%. This contributed to the annual value of $1.3 million for FY2023, which is 79740.93% up from last year.
  • According to the latest figures from Q4 2023, Alaunos Therapeutics' Cash from Investing Activities is $1.5 million, which was up 171612.9% from $1000.0 recorded in Q3 2023.
  • Alaunos Therapeutics' Cash from Investing Activities' 5-year high stood at $1.5 million during Q4 2023, with a 5-year trough of -$3.8 million in Q4 2020.
  • In the last 5 years, Alaunos Therapeutics' Cash from Investing Activities had a median value of -$135000.0 in 2023 and averaged -$703411.8.
  • Per our database at Business Quant, Alaunos Therapeutics' Cash from Investing Activities plummeted by 503000.0% in 2020 and then surged by 171612.9% in 2023.
  • Quarter analysis of 5 years shows Alaunos Therapeutics' Cash from Investing Activities stood at -$10000.0 in 2019, then plummeted by 37560.0% to -$3.8 million in 2020, then surged by 90.47% to -$359000.0 in 2021, then skyrocketed by 74.09% to -$93000.0 in 2022, then skyrocketed by 1716.13% to $1.5 million in 2023.
  • Its Cash from Investing Activities was $1.5 million in Q4 2023, compared to $1000.0 in Q3 2023 and -$135000.0 in Q2 2023.